Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains
about
Effect of Native Gastric Mucus on in vivo Hybridization Therapies Directed at Helicobacter pylori.Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosisCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaComparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.Emerging agents to combat complicated and resistant infections: focus on ceftobiproleEfficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolatesAntibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection ModelComparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions.Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targetsIdentifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.Newer developments in the treatment of Gram-positive infections.Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
P2860
Q27317349-5493A6FD-2208-493D-B341-093B9BA7E9F1Q27644255-EB5363BF-FA0C-4872-88CA-3D4D93352922Q28085517-DC2DF9CC-057E-49B2-8E96-6AF35FAFD4EFQ34309620-20C8415C-F3DA-49C2-B9FA-FE9CEEA74D64Q34433342-7BEB68F1-279A-4CA2-BB5D-91AF8801B542Q35026567-BAB424C9-7FC9-410D-8DF9-0A3CB6FB7ADDQ35191501-D7426A64-7E72-44F6-B428-FB14173ECD9BQ35542062-518C98C5-789F-4E40-AAE0-E9D6029FDD3AQ35859914-99B705E9-4672-43A1-BF60-14A38006E42DQ35941253-6C9CC9CA-3F2F-4EFE-A9FF-C4A1190399ABQ36018731-7754283C-543D-469C-AC52-E084458DC1EDQ36396172-60CF6D60-84BB-46A3-8C2B-B64E17B427FAQ37115690-AEA34474-B37E-4D7A-8D7B-0AD8872B229FQ37274632-9F1521AB-87F0-4B06-8FDA-E621345FFB2CQ37274678-D118EC84-B6D1-49F1-93D8-39DF3CB4B34CQ37461413-98D37478-8A5B-4B55-8677-0D0C362338F9Q37538738-2E5AE477-F022-47BC-93C0-1E0082550B44Q37593094-4FFB83B2-F36B-42A3-83B1-838B8779D2C4Q37636151-71C8AFC2-B79E-430A-A937-20C6DF55FA26Q37643614-AC083B5F-E304-480E-A761-379A59313B72Q37927017-F8A980A9-9F6F-4B09-BC64-1E0C5E03EF14Q38099393-F0E66BC0-64F6-4DD0-8D6E-41840D50B887Q39164183-9BF01028-D8B1-4C63-BB16-81A451B5C246
P2860
Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Pharmacodynamic characterizati ...... Staphylococcus aureus strains
@ast
Pharmacodynamic characterizati ...... Staphylococcus aureus strains
@en
type
label
Pharmacodynamic characterizati ...... Staphylococcus aureus strains
@ast
Pharmacodynamic characterizati ...... Staphylococcus aureus strains
@en
prefLabel
Pharmacodynamic characterizati ...... Staphylococcus aureus strains
@ast
Pharmacodynamic characterizati ...... Staphylococcus aureus strains
@en
P2093
P2860
P356
P1476
Pharmacodynamic characterizati ...... Staphylococcus aureus strains
@en
P2093
David P Nicolau
Pamela R Tessier
Somvadee Laohavaleeson
P2860
P304
P356
10.1128/AAC.01422-07
P407
P577
2008-04-14T00:00:00Z